Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort

BMC Endocrine Disorders

Reimar W Thomsen¹  Henrik Toft Sørensen¹  Henning Beck-Nielsen²  Jens Sandahl Christiansen³  Ivan Brandslund⁴  Søren Friborg⁵  Jacob V Stidsen²  Jens Steen Nielsen²  Klara Berencsi¹  Jørgen Rungby⁶  Anil Mor¹  Elisabeth Svensson¹ 

[1] Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark;Diabetes Research Centre, Department of Endocrinology, Odense University Hospital, Odense, Denmark;Department of Internal Medicine and Endocrinology, Institute of Clinical Medicine Aarhus University Hospital, Aarhus, Denmark;Department of Biochemistry, Lillebaelt Hospital Vejle, Vejle, Denmark;Department of Endocrinology M, Odense University Hospital, Odense, Denmark;Department of Pharmacology, Institute of Clinical Medicine, University of Aarhus, Aarhus, Denmark

关键词: Physical activity;    Obesity;    Lifestyle factors;    C-reactive protein;   

Others  :  1085014
DOI  :  10.1186/1472-6823-14-74

 received in 2014-03-21, accepted in 2014-08-11,  发布年份 2014

【 摘 要 】

Background

We aimed to examine the prevalence of and modifiable factors associated with elevated C-reactive Protein (CRP), a marker of inflammation, in men and women with newly diagnosed Type 2 Diabetes mellitus (DM) in a population-based setting.

Methods

CRP was measured in 1,037 patients (57% male) with newly diagnosed Type 2 DM included in the prospective nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project. We assessed the prevalence of elevated CRP and calculated relative risks (RR) examining the association of CRP with lifestyle and clinical factors by Poisson regression, stratified by gender. We used linear regression to examine the association of CRP with other biomarkers.

Results

The median CRP value was 2.1 mg/L (interquartile range, 1.0 – 4.8 mg/L). In total, 405 out of the 1,037 Type 2 DM patients (40%) had elevated CRP levels (>3.0 mg/L). More women (46%) than men (34%) had elevated CRP. Among women, a lower risk of elevated CRP was observed in patients receiving statins (adjusted RR (aRR) 0.7 (95% confidence interval (CI) 0.6-0.9)), whereas a higher risk was seen in patients with central obesity (aRR 2.3 (95% CI 1.0-5.3)). For men, CRP was primarily elevated among patients with no regular physical activity (aRR 1.5 (95% CI 1.1-1.9)), previous cardiovascular disease (aRR1.5 (95% CI 1.2-1.9) and other comorbidity. For both genders, elevated CRP was 1.4-fold increased in those with weight gain >30 kg since age 20 years. Sensitivity analyses showed consistent results with the full analysis. The linear regression analysis conveyed an association between high CRP and increased fasting blood glucose.

Conclusions

Among newly diagnosed Type 2 DM patients, 40% had elevated CRP levels. Important modifiable risk factors for elevated CRP may vary by gender, and include low physical activity for men and central obesity and absence of statin use for women.

【 授权许可】

   
2014 Svensson et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB: C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004, 27:889-894.
• [2]Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S: Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care 2012, 35:396-403.
• [3]Ong KL, Allison MA, Cheung BM, Wu BJ, Barter PJ, Rye KA: Trends in C-reactive protein levels in US adults from 1999 to 2010. Am J Epidemiol 2013, 177:1430-1442.
• [4]Ford ES, Liu S, Mannino DM, Giles WH, Smith SJ: C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. Eur J Clin Nutr 2003, 57:1157-1163.
• [5]Rojo-Martinez G, Soriguer F, Colomo N, Calle A, Goday A, Bordiu E, Delgado E, Menendez E, Ortega E, Urrutia I, Girbes J, Castano L, Catala M, Gaztambide S, Valdes S: Factors determining high-sensitivity C-reactive protein values in the Spanish population. [e-mail] study. Eur J Clin Invest 2013, 43:1-10.
• [6]Albert MA, Glynn RJ, Ridker PM: Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003, 107:443-447.
• [7]Hung J, Knuiman MW, Divitini ML, Davis T, Beilby JP: Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am J Cardiol 2008, 101:193-198.
• [8]Hirata A, Ohnaka K, Morita M, Toyomura K, Kono S, Yamamoto K, Adachi M, Kawate H, Takayanagi : Behavioral and clinical correlates of high-sensitivity C-reactive protein in Japanese men and women. Clin Chem Lab Med 2012, 50:1469-1476.
• [9]Thomsen RW, Friborg S, Nielsen JS, Schroll H, Johnsen SP: The Danish centre for strategic research in type 2 diabetes (DD2): organization of diabetes care in Denmark and supplementary data sources for data collection among DD2 study participants. Clin Epidemiol 2012, 4:15-19.
• [10]Thomsen RW, Nielsen JS, Ulrichsen SP, Pedersen L, Hansen AM, Nilsson T: The Danish centre for strategic research in type 2 diabetes (DD2) study: collection of baseline data from the first 580 patients. Clin Epidemiol 2012, 4:43-48.
• [11]Nielsen JS, Thomsen RW, Steffensen C, Christiansen JS: The Danish centre for strategic research in type 2 diabetes (DD2) study: implementation of a nationwide patient enrollment system. Clin Epidemiol 2012, 4:27-36.
• [12]Pedersen CB, Gotzsche H, Moller JO, Mortensen PB: The Danish civil registration system. A cohort of eight million persons. Dan Med Bull 2006, 53:441-449.
• [13]Lynge E, Sandegaard JL, Rebolj M: The Danish national patient register. Scand J Publ Health 2011, 39:30-33.
• [14]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
• [15]Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT: The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish national registry of patients. BMC Med Res Methodol 2011, 11:83. BioMed Central Full Text
• [16]Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT: Existing data sources for clinical epidemiology: the Danish national database of reimbursed prescriptions. Clin Epidemiol 2012, 4:303-313.
• [17]Pearson TA, Mensah GA, Hong Y, Smith SC Jr: CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: overview. Circulation 2004, 110:e543-e544.
• [18]Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999, 22:1971-1977.
• [19]Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM, de Lemos JA: Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab 2009, 94:3251-3258.
• [20]Taylor F, Ebrahim S: Statins work just as well in women as in men: comment on “Statin therapy in the prevention of recurrent cardiovascular events”. Arch Intern Med 2012, 172:919-920.
• [21]Bertoni AG, Burke GL, Owusu JA, Carnethon MR, Vaidya D, Barr RG, Jenny NS, Ouyang P, Rotter JI: Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010, 33:804-810.
• [22]Ajani UA, Ford ES, Mokdad AH: Prevalence of high C-reactive protein in persons with serum lipid concentrations within recommended values. Clin Chem 2004, 50:1618-1622.
• [23]Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T: High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006, 29:329-333.
• [24]Bruno G, Fornengo P, Novelli G, Panero F, Perotto M, Segre O, Zucco C, Deambrogio P, Bargero G, Perin PC: C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes 2009, 58:926-933.
• [25]Brunner EJ, Kivimaki M, Witte DR, Lawlor DA, Davey SG, Cooper JA, Miller M, Lowe GD, Rumley A, Casas JP, Shah T, Humphries SE, Hingorani AD, Marmot MG, Timpson NJ, Kumari M: Inflammation, insulin resistance, and diabetes–Mendelian randomization using CRP haplotypes points upstream. PLoS Med 2008, 5:e155.
• [26]Vepsalainen T, Soinio M, Marniemi J, Lehto S, Juutilainen A, Laakso M, Ronnemaa T: Physical activity, high-sensitivity C-reactive protein, and total and cardiovascular disease mortality in type 2 diabetes. Diabetes Care 2011, 34:1492-1496.
• [27]Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Heise T, Heinemann L, Roden M, Schloot NC: Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One 2012, 7:e33108.
• [28]Hopps E, Canino B, Caimi G: Effects of exercise on inflammation markers in type 2 diabetic subjects. Acta Diabetol 2011, 48:183-189.